REDX PHARMA LIMITED

("Redx" or the "Company")

Redx Presents Preclinical Data on RXC008, a Potential First-in-Class Therapy to Treat Fibrostenotic Crohn's Disease, at the UEG Week

Presentation submission wins Top Abstract Prize

The oral presentation, entitled "RXC008: First-in-Class Gastrointestinal-Targeted Potent Pan-ROCK Inhibitor for Treatment of Fibrostenotic Crohn's Disease", was delivered on Monday 14 October, during the session: IBD: New horizons in medical treatment – Part 1

RXC008 is currently in phase 1 clinical development where results from healthy volunteer cohorts are expected to be available by the end of 2024

Alderley Park, UK, 14 October 2024 Redx Pharma (JPJ:REDX), the clinical-stage, small molecule biotechnology company, today presents on RXC008, at the United European Gastroenterology (UEG) Week Congress, October 12-15, Vienna, Austria.

RXC008 is a gastrointestinal (GI)-restricted highly potent and selective pan-ROCK inhibitor, currently in phase 1 clinical development to treat fibrostenotic Crohn's disease, where results from healthy volunteer cohorts are expected to be available before year end.

The presented preclinical results included data demonstrating RXC008's strong anti-fibrotic therapeutic effects in animal models of inflammatory bowel disease and confirms the cardiovascular safety profile of a GI-restricted pan-ROCK inhibitor through animal toxicology studies.

Dr Elaine Kilgour, Head of Translational Science, Redx, and lead author of the abstract, has been awarded a UEG Top Abstract Prize, one of five awarded to the first author of abstracts submitted to this year's Congress. Abstracts are eligible for this prize if they have not been previously presented at an international meeting. UEG Week is the largest annual GI-focussed congress in Europe. It features the latest advances in clinical management and research in the field of digestive and liver disease. UEG is the leading non-profit organisation for excellence in digestive health in Europe. Their mission is to improve the prevention and care of digestive diseases through providing top tier education, supporting research and advancing clinical standards.

Dr Elaine Kilgour, Head of Translational Science, Redx, and lead author of the abstract, said: "We are excited to be developing a novel compound for the debilitating indication of fibrostenotic Crohn's disease. RXC008 has demonstrated encouraging findings in preclinical studies. Its marked antifibrotic effect, yet GI-restriction bodes well for its potential in the clinic."

Dr Helen Timmis, Interim Chief Medical Officer at Redx added: "RXC008 holds great promise as a novel treatment for fibrostenotic Crohn's disease. There are currently no approved therapies for treating underlying progressive fibrosis of the intestine which leads to stricturing and penetrating disease. Anti-inflammatories suppress inflammation but do not treat the underlying fibrosis, leaving patients with invasive surgical interventions as their only therapeutic option".

Rho-associated coiled-coil forming protein kinase (ROCK) is well established as an anti-fibrotic target and is known to consist of two isoforms ROCK 1 and 2. RXC008 is a potent, oral, small molecule non-systemic ROCK 1/2 inhibitor that avoids the significant cardiovascular side effects of systemic pan-ROCK inhibitors, including tachycardia and hypotension, by being restricted to the GI-tract via high efflux and low permeability. This results in virtually no systemic breakthrough, with the molecule being rapidly metabolised by paraoxonase enzymes in the plasma should any breakthrough occur under particular circumstances.

Crohn's disease affects 1.7m[1] people globally and >70,000 new cases are diagnosed each year. More than 50% of patients[2] with Crohn's disease can develop significant fibrosis and stricture formation within ten years after diagnosis; this fibrosis associated with Crohn's disease is known as fibrostenotic Crohn's disease. The current management of fibrotic strictures of the gastrointestinal tract is primarily surgical as no drugs are specifically approved for fibrosis, which can progress despite intervention with anti-inflammatory therapies.

Oral Presentation Details:

Title: *RXC008: First-in-Class Gastrointestinal-Targeted Potent Pan-ROCK Inhibitor for Treatment of Fibrostenotic Crohn's Disease*

Session: *IBD: New horizons in medical treatment - Part 1*

Day/Date: *Monday 14 October 2024*

Presentation Time: *10:00-10:12 CEST*

---

[1] Clarivate, Crohn's disease landscape & forecast p.g. 39, Published Sep 2022

[2] Chan et al, 2018

Location: *Messe Wien Exhibition & Congress Center, Messe Wien, Entrance A, Messeplatz 1, 1020 Vienna, Austria*

A copy of the abstract presentation deck will be made available on the Company website at: https://www.redxpharma.com/scientific-publications.

For further information, please contact:

Redx Pharma Limited
Erin Hamid, Interim Head of Communications
ir@redxpharma.com
T: +44 (0)1625 469 918

FTI Consulting
Simon Conway/ Ciara Martin
T: +44 (0)203 727 1000

About Redx Pharma Limited

Redx Pharma (JPJ: REDX) is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, targeted therapeutics for the treatment of fibrotic disease, cancer and the emerging area of cancer-associated fibrosis. Redx aims to progress its programmes to clinical proof of concept before evaluating options for further development and potential value creation. The Company is currently progressing an industry leading ROCK inhibitor portfolio through the clinic, including zelasudil, a selective ROCK2 inhibitor for the treatment of interstitial lung diseases including idiopathic pulmonary fibrosis and RXC008, a GI-targeted pan-ROCK inhibitor for the treatment of fibrostenotic Crohn's disease. Additionally, the Company has a Phase 2 precision oncology programme which it intends to partner for further development.

The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets. To date, six Redx discovered molecules have been progressed into the clinic with the Company's accomplishments evidenced not only by its wholly-owned clinical-stage product candidates and discovery pipeline, but also by its strategic transactions, which includes the sale of pirtobrutinib (RXC005, LOXO-305), the only non-covalent or reversible BTK inhibitor now approved by the US FDA, and transactions with both AstraZeneca and Jazz Pharmaceuticals.